Updates on OLUMIANT® (baricitinib) Phase 3 lupus progra

/PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ:INCY) today announced updates on the Phase 3 development program for OLUMIANT®...

Related Keywords

Japan , United States , Delaware , Spain , Spanish , Catalina Loveman , Kevin Hern , Christine Chiou , Marlo Scott , Eli Lilly , World Health Organization , Drug Administration , Given The Agency , Abnormal Laboratory , Exchange Commission , European Union , Complete Response Letter , Lotus Mallbris , Ruse Under , Important Safety Information , Emergency Use Authorization , Fact Sheet , Healthcare Providers , Safety Information , Emergency Use , Laboratory Values , Prescribing Information , Medication Guide , Specific Populations , Boxed Warning , Serious Infections , Major Adverse Cardiovascular Events , Liver Enzyme Elevations , Private Securities Litigation Reform Act , United States Securities , Eli Lilly And Company ,